{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:36:08Z","timestamp":1785854168925,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Special Support Project for High-level Talents of Shaanxi Province","award":["2020"],"award-info":[{"award-number":["2020"]}]},{"name":"the Shaanxi Provincial Key Research and Development Project","award":["2020GXLH-Y-027"],"award-info":[{"award-number":["2020GXLH-Y-027"]}]},{"name":"the Scientific Research Project of Xi'an Health Commission","award":["2020qn16"],"award-info":[{"award-number":["2020qn16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aims to analyze adverse drug events (ADE) related to romosozumab from the second quarter of 2019 to the third quarter of 2023 from FAERS database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The ADE data related to romosozumab from 2019 Q2 to 2023 Q3 were collected. After data normalization, four signal strength quantification algorithms were used: ROR (Reporting Odds Ratios), PRR (Proportional Reporting Ratios), BCPNN (Bayesian Confidence Propagation Neural Network), and EBGM (Empirical Bayesian Geometric Mean).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Screening for romosozumab-related AEs (adverse events) included 23 system organ categories (SOCs). PT (preferred terms) levels were screened for adverse drug reaction (ADR) signals. A total of 7055 reports with romosozumab as the primary suspect (PS) and 14,041 PTs induced by romosozumab as PS were identified. Common significant signals of general disorders and administration site conditions, musculoskeletal and connective tissue disorders have emerged. Specifically, unexpected AEs such as gastrointestinal disorder, respiratory, thoracic and mediastinal disorders also occur. Notably, fracture (n\u2009=\u2009503, ROR\u2009=\u2009107.8, PRR\u2009=\u2009103.83, IC\u2009=\u20096.6, EBGM\u2009=\u200997.02) and bone density abnormal (n\u2009=\u2009429, ROR\u2009=\u2009343.65, PRR\u2009=\u2009332.77, IC\u2009=\u20098.08, EBGM\u2009=\u2009271.34) exhibited relatively high occurrence rates and signal strengths.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our study identifies potential new AE signals and provides broader data support for the safety of romosozumab. In clinical application, doctors are provided with a warning to closely monitor adverse reactions to support their rational use in diseases such as osteoporosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40520-024-02921-5","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:32:04Z","timestamp":1736865124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023"],"prefix":"10.1007","volume":"37","author":[{"given":"Luyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dageng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"2921_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155638","volume":"145","author":"E Gielen","year":"2023","unstructured":"Gielen E et al (2023) Sarcopenia, osteoporosis and frailty. Metabolism 145:155638","journal-title":"Metabolism"},{"key":"2921_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/joim.12369","volume":"277","author":"M Lorentzon","year":"2015","unstructured":"Lorentzon M, Cummings SR (2015) Osteoporosis: the evolution of a diagnosis. J Intern Med 277:650\u2013661","journal-title":"J Intern Med"},{"key":"2921_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11684-020-0748-y","volume":"15","author":"X Zhu","year":"2021","unstructured":"Zhu X, Zheng H (2021) Factors influencing peak bone mass gain. Front Med 15:53\u201369","journal-title":"Front Med"},{"key":"2921_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.mcna.2020.06.004","volume":"104","author":"CB Johnston","year":"2020","unstructured":"Johnston CB, Dagar M (2020) Osteoporosis in older adults. Med Clin North Am 104:873\u2013884","journal-title":"Med Clin North Am"},{"key":"2921_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/GRF.0000000000000572","volume":"63","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz M, Robinson K, Shibli-Rahhal A (2020) Bone health and osteoporosis prevention and treatment. Clin Obstet Gynecol 63:770\u2013787","journal-title":"Clin Obstet Gynecol"},{"key":"2921_CR6","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS et al (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102","journal-title":"Osteoporos Int"},{"key":"2921_CR7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/nu13041372","volume":"13","author":"L Di Renzo","year":"2021","unstructured":"Di Renzo L, Gualtieri P, De Lorenzo A (2021) Diet, nutrition and chronic degenerative diseases. Nutrients 13:1372","journal-title":"Nutrients"},{"key":"2921_CR8","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.3390\/jcm11092382","volume":"11","author":"MM Sobh","year":"2022","unstructured":"Sobh MM et al (2022) Secondary osteoporosis and metabolic bone diseases. J Clin Med 11:2382","journal-title":"J Clin Med"},{"key":"2921_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3803\/EnM.2021.301","volume":"36","author":"JP Brown","year":"2021","unstructured":"Brown JP (2021) Long-term treatment of postmenopausal osteoporosis. Endocrinol Metab (Seoul) 36:544\u2013552","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2921_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40266-020-00793-8","volume":"37","author":"J Paik","year":"2020","unstructured":"Paik J, Scott LJ (2020) Romosozumab: a review in postmenopausal osteoporosis. Drugs Aging 37:845\u2013855","journal-title":"Drugs Aging"},{"key":"2921_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00198-020-05639-y","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A et al (2021) Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study. Osteoporos Int 32:653\u2013661","journal-title":"Osteoporos Int"},{"key":"2921_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/jcph.2050","volume":"62","author":"CP Hsu","year":"2022","unstructured":"Hsu CP et al (2022) Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab. J Clin Pharmacol 62:1132\u20131141","journal-title":"J Clin Pharmacol"},{"key":"2921_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","volume":"106","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL, Hofbauer LC, Forfar JC (2021) Cardiovascular safety and sclerostin inhibition. J Clin Endocrinol Metab 106:1845\u20131853","journal-title":"J Clin Endocrinol Metab"},{"key":"2921_CR14","doi-asserted-by":"publisher","first-page":"174550572211255","DOI":"10.1177\/17455057221125577","volume":"18","author":"SY Lim","year":"2022","unstructured":"Lim SY (2022) Romosozumab for the treatment of osteoporosis in women: efficacy, safety, and cardiovascular risk. Womens Health (Lond) 18:17455057221125576","journal-title":"Womens Health (Lond)"},{"key":"2921_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","volume":"77","author":"C Prather","year":"2020","unstructured":"Prather C, Adams E, Zentgraf W (2020) Romosozumab: a first-in-class sclerostin inhibitor for osteoporosis. Am J Health Syst Pharm 77:1949\u20131956","journal-title":"Am J Health Syst Pharm"},{"key":"2921_CR16","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.15586\/jptcp.v27i1.655","volume":"27","author":"A Shakeri","year":"2020","unstructured":"Shakeri A, Adanty C (2020) Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: a review. J Popul Ther Clin Pharmacol 27:e25\u2013e31","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"2921_CR17","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","volume":"11","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T et al (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep 11:11801","journal-title":"Sci Rep"},{"key":"2921_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116480","volume":"162","author":"T Kobayakawa","year":"2022","unstructured":"Kobayakawa T et al (2022) Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: the prospective VICTOR study. Bone 162:116480","journal-title":"Bone"},{"key":"2921_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243\u20131256","journal-title":"Osteoporos Int"},{"key":"2921_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00223-023-01079-y","volume":"112","author":"T Oue","year":"2023","unstructured":"Oue T et al (2023) Comparison of the efficacy of zoledronate acid or denosumab after switching from romosozumab in Japanese postmenopausal patients. Calcif Tissue Int 112:683\u2013690","journal-title":"Calcif Tissue Int"},{"key":"2921_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem A et al (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med 176:224\u2013238","journal-title":"Ann Intern Med"},{"key":"2921_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s40265-020-01364-2","volume":"80","author":"NR Fuggle","year":"2020","unstructured":"Fuggle NR et al (2020) Assessment of cardiovascular safety of anti-osteoporosis drugs. Drugs 80:1537\u20131552","journal-title":"Drugs"},{"key":"2921_CR23","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","volume":"34","author":"P Chavassieux","year":"2019","unstructured":"Chavassieux P et al (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34:1597\u20131608","journal-title":"J Bone Miner Res"},{"key":"2921_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/postgradmedj-2019-136699","volume":"95","author":"M Pazianas","year":"2019","unstructured":"Pazianas M (2019) Bones, heart and the new anabolic agent romosozumab. Postgrad Med J 95:521\u2013523","journal-title":"Postgrad Med J"},{"key":"2921_CR25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-021-01587-x","volume":"81","author":"LPB Elbers","year":"2021","unstructured":"Elbers LPB, Raterman HG, Lems WF (2021) Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: a narrative review. Drugs 81:1645\u20131655","journal-title":"Drugs"},{"key":"2921_CR26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A et al (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32:1999\u20132009","journal-title":"Osteoporos Int"},{"key":"2921_CR27","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","volume":"33","author":"A Tominaga","year":"2022","unstructured":"Tominaga A et al (2022) Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment. Osteoporos Int 33:1265\u20131273","journal-title":"Osteoporos Int"},{"key":"2921_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","volume":"176","author":"C Ayers","year":"2023","unstructured":"Ayers C et al (2023) Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 176:182\u2013195","journal-title":"Ann Intern Med"},{"key":"2921_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN et al (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ 381:e068033","journal-title":"BMJ"},{"key":"2921_CR30","doi-asserted-by":"publisher","first-page":"e2924","DOI":"10.1002\/dmrr.2924","volume":"33","author":"JE Blau","year":"2017","unstructured":"Blau JE et al (2017) Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 33:e2924","journal-title":"Diabetes Metab Res Rev"},{"key":"2921_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou C et al (2023) Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine 59:101967","journal-title":"EClinicalMedicine"},{"key":"2921_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2921_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2921_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11096-010-9421-x","volume":"32","author":"JX Wei","year":"2010","unstructured":"Wei JX et al (2010) A novel method for signal detection of adverse drug reactions based on proportional reporting ratios. Pharm World Sci 32:658\u2013662","journal-title":"Pharm World Sci"},{"key":"2921_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ph14010004","volume":"14","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y et al (2020) Improved detection criteria for detecting drug-drug interaction signals using the proportional reporting ratio. Pharmaceuticals (Basel) 14:4","journal-title":"Pharmaceuticals (Basel)"},{"key":"2921_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2921_CR37","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","volume":"76","author":"K Tada","year":"2020","unstructured":"Tada K et al (2020) Borrowing external information to improve Bayesian confidence propagation neural network. Eur J Clin Pharmacol 76:1311\u20131319","journal-title":"Eur J Clin Pharmacol"},{"key":"2921_CR38","doi-asserted-by":"publisher","first-page":"1199031","DOI":"10.3389\/fphar.2023.1199031","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H et al (2023) Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol 14:1199031","journal-title":"Front Pharmacol"},{"key":"2921_CR39","doi-asserted-by":"publisher","first-page":"1182113","DOI":"10.3389\/fphar.2023.1182113","volume":"14","author":"H Zhao","year":"2023","unstructured":"Zhao H et al (2023) Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database. Front Pharmacol 14:1182113","journal-title":"Front Pharmacol"},{"key":"2921_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda T et al (2014) Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci 11:461\u2013465","journal-title":"Int J Med Sci"},{"key":"2921_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116610","volume":"167","author":"AH Seeto","year":"2023","unstructured":"Seeto AH et al (2023) Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone 167:116610","journal-title":"Bone"},{"key":"2921_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","volume":"112","author":"T Saito","year":"2023","unstructured":"Saito T et al (2023) One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int 112:34\u201344","journal-title":"Calcif Tissue Int"},{"key":"2921_CR43","first-page":"Cd013424","volume":"7","author":"T Hara","year":"2021","unstructured":"Hara T et al (2021) Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3\u20135D. Cochrane Database Syst Rev 7:Cd013424","journal-title":"Cochrane Database Syst Rev"},{"key":"2921_CR44","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. Lancet 399:1080\u20131092","journal-title":"Lancet"},{"key":"2921_CR45","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:587\u2013594","journal-title":"J Clin Endocrinol Metab"},{"key":"2921_CR46","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"2921_CR47","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183\u20133193","journal-title":"J Clin Endocrinol Metab"},{"key":"2921_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24290","volume":"24","author":"S Davis","year":"2020","unstructured":"Davis S et al (2020) Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess 24:1\u2013314","journal-title":"Health Technol Assess"},{"key":"2921_CR49","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1111\/bcp.14749","volume":"87","author":"M Tanaka","year":"2021","unstructured":"Tanaka M et al (2021) Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. Br J Clin Pharmacol 87:3279\u20133291","journal-title":"Br J Clin Pharmacol"},{"key":"2921_CR50","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","volume":"33","author":"K Ebina","year":"2022","unstructured":"Ebina K et al (2022) Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:1807\u20131813","journal-title":"Osteoporos Int"},{"key":"2921_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.afos.2021.09.002","volume":"7","author":"Y Takeuchi","year":"2021","unstructured":"Takeuchi Y (2021) Romosozumab and cardiovascular safety in Japan. Osteoporos Sarcopenia 7:89\u201391","journal-title":"Osteoporos Sarcopenia"},{"key":"2921_CR52","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.apsb.2022.01.012","volume":"12","author":"S Yu","year":"2022","unstructured":"Yu S et al (2022) Drug discovery of sclerostin inhibitors. Acta Pharm Sin B 12:2150\u20132170","journal-title":"Acta Pharm Sin B"},{"key":"2921_CR53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/CIA.S242038","volume":"15","author":"G Iolascon","year":"2020","unstructured":"Iolascon G et al (2020) Pharmacological therapy of osteoporosis: what\u2019s new? Clin Interv Aging 15:485\u2013491","journal-title":"Clin Interv Aging"},{"key":"2921_CR54","doi-asserted-by":"publisher","first-page":"707","DOI":"10.20945\/2359-3997000000566","volume":"66","author":"L Bandeira","year":"2022","unstructured":"Bandeira L, Lewiecki EM (2022) Anabolic therapy for osteoporosis: update on efficacy and safety. Arch Endocrinol Metab 66:707\u2013716","journal-title":"Arch Endocrinol Metab"},{"key":"2921_CR55","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12967-023-04563-z","volume":"21","author":"D Wu","year":"2023","unstructured":"Wu D et al (2023) Romosozumab in osteoporosis: yesterday, today and tomorrow. J Transl Med 21:668","journal-title":"J Transl Med"},{"key":"2921_CR56","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30:2437\u20132448","journal-title":"Osteoporos Int"},{"key":"2921_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","volume":"81","author":"L Chouinard","year":"2016","unstructured":"Chouinard L et al (2016) Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmacol 81:212\u2013222","journal-title":"Regul Toxicol Pharmacol"},{"key":"2921_CR58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00198-022-06642-1","volume":"34","author":"M Kashii","year":"2023","unstructured":"Kashii M et al (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34:563\u2013572","journal-title":"Osteoporos Int"},{"key":"2921_CR59","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00774-022-01332-8","volume":"40","author":"A Miyauchi","year":"2022","unstructured":"Miyauchi A et al (2022) Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab 40:677\u2013687","journal-title":"J Bone Miner Metab"},{"key":"2921_CR60","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/jbmr.4645","volume":"37","author":"NB Watts","year":"2022","unstructured":"Watts NB (2022) Romosozumab and renal function. J Bone Miner Res 37:1435\u20131436","journal-title":"J Bone Miner Res"},{"key":"2921_CR61","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ndt\/gfy129","volume":"34","author":"VM Brandenburg","year":"2019","unstructured":"Brandenburg VM et al (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34:408\u2013414","journal-title":"Nephrol Dial Transplant"},{"key":"2921_CR62","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","volume":"16","author":"S Ekins","year":"2011","unstructured":"Ekins S et al (2011) In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 16:298\u2013310","journal-title":"Drug Discov Today"},{"key":"2921_CR63","doi-asserted-by":"publisher","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","volume":"115","author":"EY Klein","year":"2018","unstructured":"Klein EY et al (2018) Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A 115:E3463\u2013E3470","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2921_CR64","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi YM, Hansen RA (2017) Empirical estimation of under-reporting in the US Food and Drug Administration adverse event reporting system (FAERS). Expert Opin Drug Saf 16:761\u2013767","journal-title":"Expert Opin Drug Saf"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-024-02921-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T02:21:32Z","timestamp":1736907692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-024-02921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2921"],"URL":"https:\/\/doi.org\/10.1007\/s40520-024-02921-5","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study data were derived from publicly available adverse event reports from FAERS, and therefore this study did not require ethics committee approval to conduct. We also solemnly promise to adhere strictly to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"23"}}